Regeneron reports response rates for multiple myeloma bispecific linvoseltamab, setting up FDA filing and showdown with J&J, Pfizer: #ASH23news2023-12-07T12:00:31+00:00December 7th, 2023|Endpoints News|
NIH to work with 10x Genomics for Alzheimer’s disease brain cell atlasnews2023-12-07T12:00:13+00:00December 7th, 2023|Endpoints News|
Wave makes $100M public offering after dosing first subjects with GSK-partnered RNA editing drugnews2023-12-07T11:53:08+00:00December 7th, 2023|Endpoints News|
AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel news2023-12-06T21:47:46+00:00December 6th, 2023|Endpoints News|
US Patent Trial and Appeal Board to reconsider Spruce patents around treatment for adrenal disordernews2023-12-06T20:16:59+00:00December 6th, 2023|Endpoints News|
Minnesota district court halts drug price transparency lawnews2023-12-06T20:02:54+00:00December 6th, 2023|Endpoints News|
Klick Health’s annual holiday greeting plays Secret Santa for its own employeesnews2023-12-06T18:56:11+00:00December 6th, 2023|Endpoints News|
FDA asks for more data from Optinose, extends review time for nasal spraynews2023-12-06T18:49:26+00:00December 6th, 2023|Endpoints News|
Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprintnews2023-12-06T18:03:50+00:00December 6th, 2023|Endpoints News|
Syros’ stock up almost 30% after positive early PhII data for blood cancer drugnews2023-12-06T16:29:26+00:00December 6th, 2023|Endpoints News|
